Literature DB >> 28112047

Venous thromboembolism during treatment with antipsychotics: Results of a drug surveillance programme.

Martin Letmaier1, Renate Grohmann2, Christiana Kren3, Sermin Toto4, Stefan Bleich4, Rolf Engel2, Thomas Gary5, Konstantinos Papageorgiou6, Anastasios Konstantinidis6, Anna Katharina Holl1, Annamaria Painold1, Siegfried Kasper6.   

Abstract

OBJECTIVES: Venous thromboembolism (VTE) can be a life-threatening medical condition that may lead to leg swelling, respiratory distress and death.
METHODS: The AMSP (Arzneimittelsicherheit in der Psychiatrie) is a continuous multicentre drug surveillance programme that assesses severe adverse drug reactions during treatment of psychiatric inpatients. We report on a total of 264,422 inpatients who were treated with antipsychotics (APs) and monitored from 1993 to 2011 in 99 psychiatric hospitals.
RESULTS: During this period VTE events were reported for 89 inpatients, corresponding to an occurrence rate of 34 cases per 100,000 inpatient admissions treated with APs or 43 cases per 10,000 person-years. The occurrence of VTE was greatest in patients over the age of 65 years of age with mood disorders. The chemical class of butyrophenones (48/100,000) followed by atypical APs (36/100,000) showed the highest occurrence rate for VTE compared to thioxanthenes (23/100,000), which were less associated with VTE. If imputed alone, pipamperone (61/100,000) and risperidone (55/100,000) were most frequently associated with VTE. In general, there was no difference in occurrence rate of VTE between high- and low-potency APs.
CONCLUSIONS: These results suggest that clinicians should consider AP drug exposure as a potential risk factor for VTE for patients older than 65 years. Additionally, the diagnosis of an affective disorder seems to increase the risk for VTE.

Entities:  

Keywords:  Venous thromboembolism; adverse drug reactions; antipsychotics; deep vein thrombosis; drug surveillance; pulmonary embolism

Mesh:

Substances:

Year:  2017        PMID: 28112047     DOI: 10.1080/15622975.2017.1285048

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  3 in total

1.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

Review 2.  Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence.

Authors:  Anna K Jönsson; Johan Schill; Hans Olsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

Review 3.  [Psychopharmacotherapy during the COVID-19 pandemic].

Authors:  J Seifert; J Heck; G Eckermann; M Singer; S Bleich; R Grohmann; S Toto
Journal:  Nervenarzt       Date:  2020-07       Impact factor: 1.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.